Comparative Pharmacology
Head-to-head clinical analysis: DURLAZA versus PLETAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURLAZA versus PLETAL.
DURLAZA vs PLETAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Durlaza (aspirin) irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting thromboxane A2 synthesis and reducing platelet aggregation.
Cilostazol inhibits phosphodiesterase III (PDE3), increasing cAMP levels in platelets and vascular smooth muscle, leading to platelet inhibition and vasodilation.
325 mg orally once daily
100 mg orally twice daily, administered at least 30 minutes before or 2 hours after meals.
None Documented
None Documented
2-4 hours (prolonged in renal impairment; up to 10-20 hours in severe impairment). Clinical dosing adjustments required when CrCl <30 mL/min.
Terminal half-life of cilostazol is approximately 11-13 hours; for active metabolites 3,4-dehydro-cilostazol (about 4-6 times more active) half-life is similar. Steady state achieved within a few days.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal. Negligible hepatic metabolism.
Renal (approximately 77% as metabolites, <1% unchanged); fecal (approximately 18%)
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent